RFH Healthcare marks historic first with administartion of Lutetium Therapy

Lutetium Therapy, a highly targeted form of radionuclide treatment, is known for its effectiveness in managing neuroendocrine tumours and metastatic prostate cancer. Previously, patients had to travel abroad—often incurring substantial financial and emotional burdens—to receive this specialised therapy. With its local availability, RFH Healthcare has redefined cancer care access for thousands across the region.

The breakthrough was made possible through RFH’s newly established Diagnostic and Cancer Treatment Centre at the RFH Specialist Hospital in Ruai, Nairobi. The facility is equipped with state-of-the-art medical technology, including Single Photon Emission Computed Tomography-CT (SPECT-CT), Positron Emission Tomography-CT (PET-CT), and a Linear Accelerator (LINAC) for high-precision radiotherapy, positioning the centre as one of the most comprehensive oncology facilities in the region.

“Our commitment is to ensure that patients across Africa can access world-class treatment without having to leave the continent,” said Dr. Maxwel Okoth, General Managing Director of RFH Healthcare. “With Lutetium therapy now available locally, we are not only saving lives, but also rewriting the future of cancer care in Africa.”

Last year, during the unveiling of the equipment, Dr. Maxwell Okoth, Group Managing Director at RFH, reaffirmed the hospital’s commitment to advancing healthcare standards:

“RFH is dedicated to setting new benchmarks in medical technology and patient care. These investments demonstrate our vision of providing world-class services locally, ensuring that Kenyans and East Africans no longer need to leave the region for critical diagnostics and treatments.”